Back HCV Treatment

HCV Treatment

Coverage of the 2016 EASL International Liver Congress

HIVandHepatitis.com coverage of the 2016 European Association for the Study of the Liver International Liver Congress (EASL 2016) in Barcelona, April 13-17, 2016.

Conference highlights include interferon-free hepatitis C treatment for people with advanced disease, experimental HCV therapy, new treatment for hepatitis B, and management of liver disease complications.

Full listing by topic

International Liver Congress website

4/22/16

alt

EASL 2016: Novel Therapy RG-101 Plus Antivirals Could Cure Hepatitis C in 4 Weeks

Two injections of RG-101, an experimental drug that targets the micro RNA miR-122 in liver cells, combined with direct-acting antiviral agents (DAAs) taken for just 4 weeks led to 12-week post-treatment sustained response in 97% of chronic hepatitis C patients, according to study results presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last week in Barcelona.

alt

Read more:

EASL 2016: $300 Hepatitis C Combination with Ravidasvir to Enter Clinical Trials

The Drugs for Neglected Diseases Initiative (DNDi) is launching clinical trials in Thailand and Malaysia to test a combination of sofosbuvir and ravidasvir, an NS5A inhibitor, in at least 800 people with all genotypes of hepatitis C virus (HCV). The combination, manufactured by Egyptian company Pharco, could be made available for $300 for a course of treatment if it proves safe and effective, DNDi executive director Bernard Pécoul announced ahead of the 2016 EASL International Liver Congress this week in Barcelona. The studies will aim to test an affordable pangenotypic combination and to provide data for regulatory submission.

alt

Read more:

EASL 2016: Shifting Hepatitis C Treatment to Primary Care Providers Could Expand Availability

Hepatitis C treatment managed by non-specialists such as primary care physicians and nurse practitioners is as safe and effective as treatment delivered by specialists -- even for challenging patient groups -- and could help increase the number of people receiving therapy, according to findings from the ASCEND study presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this week in Barcelona.

alt

Read more:

EASL 2016: Sofosbuvir, Velpatasvir, and GS-9857 Works Well for Treatment-Experienced HCV Patients

A triple combination of Gilead Sciences' sofosbuvir, velpatasvir, and GS-9857 demonstrated a high sustained response rate for treatment-experienced people with all hepatitis C virus (HCV) genotypes who previously were not cured with prior direct-acting antivirals (DAAs), according to 2 presentations at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this week in Barcelona.

alt

Read more: